The Journal of American College of Cardiology has published the results from Corindus Vascular Robotics’ CorPath PRECISE (Percutaneous Robotic-Enhanced Coronary Intervention) study in the April 2013 issue. Results of the trial demonstrate the CorPath System is safe and feasible for patients, with significantly lower harmful radiation exposure to the operator.

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Medical Imaging Electronics (MiE) and Nuclear Imaging Services (NIS) ECAT Scintron. It is the only upgrade path available to the Siemens ECAT 47, ECAT HR+, and ECAT Accel positron emission tomography (PET) systems. The ACSII and SUN workstation are removed from the system and replaced with new PC-based technology that provides new and existing users of the ECAT series PET systems access to faster processing speeds, new acquisition protocols and parts availability. With improved reliability and longevity, the ECAT Scintron redefines the life cycle of dedicated PET systems in the U.S. market.

 

New research presented at Heart Rhythm 2013 continues to show promising results for focal impulse and rotor modulation (FIRM) mapping to effectively target atrial fibrillation (AF) sources and improves ablation therapy outcomes. The novel diagnostic real-time mapping system helps target ablation therapy to patient-specific drivers of AF rather than to anatomical targets, which can improve patient outcomes.

The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and persists for at least three years after index hospitalization with infection. These are the key findings of a retrospective cohort study of 200,219 Medicare fee-for-service patients undergoing cardiac device procedures, with and without infection, that were presented today by M. Rizwan Sohail, M.D., a researcher from the Mayo Clinic divisions of infectious diseases and cardiovascular diseases, at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.
VAD wireless power transfer system

Leviticus Cardio performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75 percent full system efficiency rate as compared with 78 percent efficiency in vitro.

New data from 100,438 patients with Boston Scientific implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) followed in the Latitude Patient Management System demonstrate the battery life of Boston Scientific single-chamber ICDs, dual-chamber ICDs and CRT-Ds are projected to last an average of 13.2, 11.5 and 9.2 years, respectively

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now